Federal appeals court bats back claims Novo Nordisk’s diabetes drug triggers pancreatic cancer
A federal appeals court upheld a win for Novo Nordisk this week, tossing out claims that its type 2 diabetes drug Victoza can cause pancreatic cancer.
The case stems back to multidistrict litigation from 2013 in which 1,500 plaintiffs accused several pharma companies of failing to warn of a potential link between their type 2 diabetes drugs and an increased risk of pancreatic cancer — including AstraZeneca’s Byetta, Novo Nordisk’s Victoza, and Merck’s Januvia and Janumet.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.